Welcome to our dedicated page for PAVmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on PAVmed stock.
PAVmed Inc. (Nasdaq: PAVM) is a cutting-edge medical device company focused on bringing innovative medical technologies from concept to commercialization with exceptional speed and efficiency. Headquartered in New York, PAVmed is led by three seasoned medical device entrepreneurs. The company is structured to develop and commercialize a diversified pipeline of breakthrough products that address unmet clinical needs, thereby enhancing and accelerating value creation through a business model centered on capital and time efficiency.
PAVmed operates in a single segment as a medical technology company, with three primary lines of business: Diagnostics, Medical Devices, and Digital Health. Through its majority-owned subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), the company offers products such as the EsoGuard Esophageal DNA Test and the EsoCheck Esophageal Cell Collection Device. These tools are designed for the early detection of esophageal precancer, aiming to prevent esophageal cancer by identifying at-risk patients early.
Another significant subsidiary is Veris Health Inc., which focuses on enhanced personalized cancer care through remote patient monitoring. Veris is developing an innovative implantable physiological monitor that interfaces with the Veris Cancer Care Platform, providing real-time health data to improve patient outcomes.
Recent notable achievements include a partnership between Lucid Diagnostics and the Esophageal Cancer Action Network (ECAN) to promote Esophageal Cancer Awareness Month, highlighting the critical link between chronic heartburn and esophageal cancer. Additionally, Lucid has published positive data from a National Cancer Institute-sponsored clinical validation study, which demonstrated EsoGuard's unprecedented early detection capabilities for esophageal precancer compared to traditional endoscopic methods.
PAVmed's commitment to innovation is further exemplified by its business updates and financial results discussions, providing shareholders and potential investors with transparent insights into the company's operational progress and strategic direction. The company's diversified approach in the medical technology sector positions it as a significant player in advancing healthcare and improving patient outcomes.
Lucid Diagnostics Inc. (NASDAQ: LUCD) reported its Q2 2024 financial results and business update. Key highlights include:
- EsoGuard® test volume increased 31% quarterly and 44% annually
- EsoGuard revenue was $1.0M, flat compared to Q1 but up 514% year-over-year
- 3,147 commercial EsoGuard tests performed, a single-quarter record
- Positive clinical data released from ENVET-BE and ESOGUARD BE-1 studies
- Cash and cash equivalents of $24.9M as of June 30, 2024
- GAAP net loss of $11.0M or $(0.23) per share
- Non-GAAP adjusted loss of $9.7M or $(0.20) per share
The company is focused on securing broad coverage and reimbursement to drive EsoGuard revenue growth.
Lucid Diagnostics (Nasdaq: LUCD) successfully completed its first major directly-contracted #CheckYourFoodTube Precancer Testing Event in partnership with the Fort Worth Fire Department (FWFD) and Front Line Mobile Health. Nearly 200 firefighters underwent testing using Lucid's EsoGuard® Esophageal DNA test and EsoCheck® Esophageal Cell Collection Device.
FWFD Fire Chief Jim Davis emphasized the importance of early detection, citing his personal loss to esophageal cancer. Lucid's President and COO, Shaun O'Neil, highlighted the potential for directly contracting with self-insured entities to contribute to long-term revenue growth. The event garnered local media coverage and addressed the increased risk of esophageal cancer among firefighters.
Lucid Diagnostics (Nasdaq: LUCD) has released new real-world data from its ENVET-BE study, demonstrating the clinical utility of the EsoGuard® Esophageal DNA test as a non-invasive triage tool for detecting esophageal precancer and cancer. The study showed that patients triaged to invasive upper endoscopy (EGD) following a positive EsoGuard test had a 2.4-fold increase in positive yield compared to screening EGD alone in at-risk patients.
Key findings include:
- EGD confirmed Barrett's Esophagus (BE) in 50 out of 199 patients who received a positive EsoGuard result
- Post-triage EGD yield was 25%, compared to the expected 11% yield of EGD as a standalone screening tool
- Results support the use of EsoGuard as an alternative to EGD for esophageal precancer testing, potentially increasing compliance with screening guidelines and reducing esophageal cancer deaths
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), has announced its participation in two upcoming investor conferences. The company will attend the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 12-13, 2024. Additionally, Lucid will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024, at 1:30 PM ET.
Investors can access the live and archived webcast of the Canaccord Genuity fireside chat through the provided link or by visiting the Investor Relations Section of the Lucid Diagnostics website. A replay of the webcast will be available on the website for 30 days following the live broadcast.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company, has announced a business update conference call and webcast scheduled for August 13, 2024, at 8:30 AM ET. During the call, Chairman and CEO Lishan Aklog, M.D., will provide an overview of the company's operations and growth strategy, while President and CFO Dennis McGrath will discuss second quarter 2024 financial results.
Investors can access the webcast through PAVmed's website or join the conference call by dialing 1-800-836-8184 (U.S.) or 1-646-357-8785 (international). The call name is "PAVmed Business Update". A 30-day replay will be available on the company's website following the call.
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company, has announced a business update conference call and webcast scheduled for August 12, 2024, at 8:30 AM ET. The event will feature:
- A business update and overview of operations by CEO Lishan Aklog, M.D.
- Discussion of the company's growth strategy
- Presentation of Q2 2024 financial results by CFO Dennis McGrath
Interested parties can access the webcast via the investor relations section of luciddx.com. For telephone access, U.S. callers should dial 1-800-836-8184, while international listeners should use 1-646-357-8785. The conference call name is "Lucid Diagnostics Business Update". A 30-day replay will be available on the company's website after the call.
Lucid Diagnostics Inc. (Nasdaq: LUCD) reported a record-breaking quarter for its EsoGuard® Esophageal DNA test volume. In Q2 2024, the company performed 3,174 tests, marking a 31% increase from Q1. This growth is attributed to expanded awareness and demand for EsoGuard esophageal precancer testing across various healthcare settings.
CEO Lishan Aklog emphasized the company's focus on increasing access to EsoGuard testing. Lucid expects to release full Q2 2024 results in mid-August. Additionally, the company held a productive meeting with CMS Medicare Administrative Contractor Palmetto GBA's Molecular Diagnostics Program (MolDX), which included key executives and medical experts in gastroenterology.
Lucid Diagnostics (Nasdaq: LUCD), a company focused on cancer prevention medical diagnostics, has launched a newly redesigned corporate website (www.luciddx.com) as announced on July 11, 2024. This improved platform aims to provide an enhanced user experience for patients, healthcare professionals, investors, and other stakeholders. According to Jenna Mowatt, Vice President of Marketing and Communications, the website is designed to reflect the company's mission to prevent esophageal cancer and showcase its innovative technologies through a modern design and comprehensive content. Lucid Diagnostics encourages visitors to explore the new website for more information.
Lucid Diagnostics announced positive results from its ESOGUARD BE-1 clinical validation study for EsoGuard, a test for detecting esophageal precancer. The study showed an 87.5% sensitivity and a 98.6% negative predictive value (NPV). The study was conducted across multiple international centers, including major U.S. and European institutions. The results support the upcoming Medicare LCD pre-submission and ongoing commercial payor engagements. The study involving 93 subjects confirmed the test's efficiency and safety, potentially making esophageal cancer screening more accessible and effective.
PAVmed's subsidiary, Veris Health, has launched a pilot program in collaboration with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). This program marks the first enrollment of patients on the Veris Cancer Care Platform, a comprehensive digital tool designed to enhance personalized cancer care. The platform integrates remote physiological data collection, symptom reporting, telehealth, and electronic health record capabilities. Cancer patients utilize the VerisBox and a patient portal for seamless data transmission and monitoring. Veris is also developing an implantable physiological monitor to complement the platform. The collaboration aims to improve early complication detection, reduce unplanned hospitalizations, and increase patient satisfaction.
FAQ
What is the current stock price of PAVmed (PAVM)?
What is the market cap of PAVmed (PAVM)?
What does PAVmed Inc. do?
What are PAVmed's main products?
What is EsoGuard?
Who leads PAVmed Inc.?
What recent achievements has PAVmed made?
What is Veris Health?
How does PAVmed enhance value creation?
What areas does PAVmed operate in?
How can I access PAVmed's latest updates?
Where can I find more information about PAVmed?
